Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + Rituximab vs Dexamethasone for Initial ITP Treatment
NCT01734057Phase 3Withdrawn
- Sponsor
- Shandong University
- Start
- Jul 2012
- Primary completion
- Jul 2013
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human thrombopoietin and rituximab in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoints: Evaluation of platelet response (Chronic ITP) at 1 year, Evaluation of platelet response (Complete Response) at 1 year and 1 more. Planned start Jul 2012; status: withdrawn.
02
Drugs
recombinant human thrombopoietinrituximab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01734057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734057.